First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial için istatistikler
Toplam ziyaret
views | |
---|---|
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial | 0 |
Aylık toplam ziyaret
views | |
---|---|
Ocak 2024 | 0 |
Şubat 2024 | 0 |
Mart 2024 | 0 |
Nisan 2024 | 0 |
Mayıs 2024 | 0 |
Haziran 2024 | 0 |
Temmuz 2024 | 0 |